Valueinvestor0909
Valueinvestor0909
Value with growth Investor. https://twitter.com/ValueIn72055855
PerformanceCommunity EngagementCommunity Endorsement

Ranked

#223

Followers
27
23.0% pa
Since March 2019
9.5%
last 3 months
20.3%
last 6 months
38.4%
last 12 months
Activity feed filter options
Edited their valuation for rhipe Limited of $2.50
2 days ago
Justification
Update based on 1H FY2021 update. Japan has more than 10000 O365 seats - that's impressive in the first year. Look at my bull case in straw. Old: Update based on FY2020 results. ( Conservative view - haven't baked in Japan growth) Old: ($2.10) updates after 1H2020 results. Old: ($2.20) Valuation update based on a guidance update.. Updates after AGM 2019 Kee
Read more
Voted on a straw in #Thesis Broken for Plexure Group Limited by CanadianAussie
6 days ago
#Thesis Broken

Resignation of CFO Andrew Dalziel

Plexure advises that CFO Andrew Dalziel has resigned.

 

Dalziel had been with the company nearly 5 years and played an important role in the company's turnaround. I outlined in my initial thesis I would consider selling if any of Norman, Dalziel or Herbison left and have to stay true to this.

Of additional concern is a lack of new customer signings, a deteriorating company culture and difficulty executing their growth strategy.

 

Voted on a straw in #Bull Case for Austco Healthcare Limited by Wini
2 weeks ago
#Bull Case

Austo Healthcare (AHC) is a provider of nurse call systems and software for hospitals and aged care facilities. Their Tacera system is best-in-class with recent R&D efforts to allow for real-time location of nurse staff to automate procedures, provide efficiencies and generate actionable data for customers.

Covid impacted the business heavily as they were unable to access sites to perform installations, upgrades and maintenance easily. This can be seen in the revenue chart below as revenues fell sharply in 2H20 and 1H21.

However the company continued to win new contracts and this resulted in a record order book which is now being eaten into with the recent FY21 update confirming 2H21 has seen a return to the $16-17m revenue of 2019. Interestingly, despite calling out a record order book at both the FY20 and 1H21 results, management confirmed the book continues to grow and is still at a record level despite the increased revenue meaning they are replenishing the orders faster than booking revenue even as restrictions are removed.

Read more
Voted on a straw in #Financials for Austco Healthcare Limited by Wini
2 weeks ago
#Financials

AHC have spent the last couple of years trying to shift their business model while also contending with US/China tariffs and then Covid-19.

I think management should be commended on the results they have achieved so far to try and move the business from a lower margin pure hardware business to a higher margin hardware/software business.

As can be seen in the image below, the business began to shift production from a reliance on Chinese suppliers to several outsourced manufacturers around the world to the point where their Dallas manufacturing plant was closed in December 2020.

A combination of growing higher margin software revenue and outsourcing lower margin manufacturing saw gross margins grow from 44% to nearly 53% in 2H20 despite Covid affected revenue and the onset of higher shipping costs from Covid disruptions.

The FY21 report will be interesting to see where margins land with manufacturing now fully outsourced and the effects of Covid beginning to dissipate in key markets. 

Read more
Voted on a valuation for Austco Healthcare Limited by Wini
2 weeks ago
Justification
Backing out grant incomes and legal settlements from FY21 guidance provided last week, I estimate AHC is doing $800k to $1.3m in the 2H21 which is still Covid affected. Assuming no further Covid disruptions I expect that sort of profitability can be maintained meaning FY22 could do $2-3m as the backlog of revenue gets booked and higher margins flow through. 16c is close enough to 15x earnings which seems reasonable given healthcare tailwinds and the on-going shift to higher software revenues.
Read more